Last update 21 Mar 2024

Reflex Sympathetic Dystrophy

Last update 21 Mar 2024

Basic Info

Synonyms

ABC症候群, Algodystrophic Syndrome, Algodystrophies

+ [116]

Introduction

A syndrome characterized by severe burning pain in an extremity accompanied by sudomotor, vasomotor, and trophic changes in bone without an associated specific nerve injury. This condition is most often precipitated by trauma to soft tissue or nerve complexes. The skin over the affected region is usually erythematous and demonstrates hypersensitivity to tactile stimuli and erythema. (Adams et al., Principles of Neurology, 6th ed, p1360; Pain 1995 Oct;63(1):127-33)

Drugs associated with Reflex Sympathetic Dystrophy

Lenalidomide

Target

CK1α x CRBN x IFNγ x IKZF1 x IKZF3 x IL-2 x IL-6 x TNF-α

Mechanism

CK1α inhibitors [+7]

Active Org.

Bristol-Myers Squibb Pharma EEIG [+20]

Originator Org.

Celgene Corp.

Active Indication

Transfusion dependent anaemia [+57]

Inactive Indication

Aase Smith Syndrome 2 [+118]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date27 Dec 2005

133

Clinical Trials associated with Reflex Sympathetic Dystrophy

NCT06302920 / Not yet recruitingNot ApplicableIIT

Investigation of the Effect of Kinesiotaping on Pain, Swelling and Kinesiophobia in Patients Diagnosed With Complex Regional Pain Syndrome

Patients will be divided into 2 groups according to the random numbers table, and both groups will receive a conventional physical therapy and rehabilitation program and nutritional support. Afterwards, edema-reducing kinesiotaping will be applied to one group. The applied kinesio tape will remain on the patient for 5 days and will be taped again after 2 days without tape. In this way, taping will be done 3 times in total, once a week for 3 weeks. During this period, patients will continue their routine physical therapy program and measurements will be taken by the same researcher in the 1st week of treatment and 3 weeks later.

Start Date20 May 2024

Sponsor / Collaborator-

NCT06306157 / Not yet recruitingPhase 4IIT

Low Dose Naltrexone (LDN) Therapy for Complex Regional Pain Syndrome (CRPS): A Feasibility Study

Complex Regional Pain Syndrome (CRPS) is a rare and often debilitating chronic pain condition whereby individuals may experience extreme sensitivity, discoloration, and swelling of the affected area -- along with numerous other painful symptoms. There are currently a limited number of treatment options available to those suffering with the condition, with various treatments including nerve blocks, neuropathic medications, and desensitization physical therapy modules. There is budding interesting in the role naltrexone, an opiate antagonist, may play in the pain management of CRPS when prescribed in very low doses. This study aims to collect preliminary data on pain scores, symptom severity, and side-effects in patients with Complex Regional Pain Syndrome randomized to receive low dose naltrexone or placebo capsules. Enrollment of 40 patients total will occur over two years from study start to study end. Each patient will be randomized to receive placebo capsules or active low dose naltrexone capsules, with both the patient and treating clinician blind to the randomization. Each patient will be actively enrolled in the study for six months and will take the medication daily at the instructed dose for the respective duration of time. Following the initial visit and study enrollment, the investigators are asking each patient to return for three (3) in-person follow-up office visits. These office visits will occur 1 month after the patient starts the medication, 3 months afterwards, and 6 months afterwards. The final 6-month office visit will mark the conclusion of the patient's active participation in the study.

Start Date01 Apr 2024

Sponsor / Collaborator

Hospital for Special Surgery

NCT05998889 / RecruitingNot ApplicableIIT

A Feasibility Study of a Combination of Graded Pain Exposure and Graded Motor Imagery in People With Complex Regional Pain Syndrome Type 1

Background:
There is low quality evidence supporting the use of rehabilitation in Complex Regional Pain Syndrome (CRPS), despite it is the first line approach in the Guidelines . Graded Motor Imagery (GMI) may be useful to improve pain and function at mid term (6 months). Graded Pain Exposure Approaches (GPE) seem to improve pain but not function at mid term. In other type of chronic pain conditions GPE offers better outcomes than "pain contingent" (exercises avoiding pain) approaches at short term (3 months) and similar at mid term. Following the recommendations of Authors, we will evaluate the efficacy and safety of a combined therapy of GMI and GPE in people with CRPS type 1.
Objective:
To evaluate the feasibility of a combined therapy of GPE and GMI in front of only GMI in people with CRPS-1 and the clinical impact on the primary outcome (Severity of the disease) of the intervention.
Design:
Feasibility Randomized controlled Trial, single blind of evaluator, 2 parallel arms. Measurement pre-intervention, post-intervention , 1 and 3 months follow-up.
Population:
People 18 years old or above with CRPS type 1 diagnosed by Budapest criteria and (1) without any psychological or psychiatric disease, (2) nor any neurosensorial issue that could compromise the realization of the therapy proposed (3) neither any major surgery intervention related to CRPS (e.g neurostimulation or sympathectomy) (4) nor minor intervention on the last 3 months (e.g. nerve blocks).
Outcomes:
Primary outcomes: Complex Regional Pain Syndrome Severity Scale (severity of the disease) and Safety Outcomes ( oedema, pain, temperature, Range of Motion). Secondary outcomes: 5Q-5D-5L (quality of life), SF-MPQ (Quality, Intensity and location of pain), PPT (pain pressure threshold), CPM ( pain inhibition pathways), FAAM or Quick Dash (function), PCS (catastrophism), Self efficacy in chronic pain questionnaire (self-efficacy), Dynamometry (Hand Grip strength),

Start Date25 Jan 2024

Sponsor / Collaborator

Institut Català de la Salut

100 Clinical Results associated with Reflex Sympathetic Dystrophy

100 Translational Medicine associated with Reflex Sympathetic Dystrophy

0 Patents (Medical) associated with Reflex Sympathetic Dystrophy

3,606

Literatures (Medical) associated with Reflex Sympathetic Dystrophy

13 Feb 2024·Orphanet journal of rare diseases

Recommendations for optimal interdisciplinary management and healthcare settings for patients with rare neurological diseases.

Article

Author: Holm Graessner ; Carola Reinhard ; Tobias Bäumer ; Annette Baumgärtner ; Knut Brockmann ; Norbert Brüggemann ; Eva Bültmann ; Jeanette Erdmann ; Kirstin Heise ; Günter Höglinger ; Irina Hüning ; Frank J Kaiser ; Christine Klein ; Thomas Klopstock ; Ingeborg Krägeloh-Mann ; Markus Kraemer ; Kerstin Luedtke ; Martin Mücke ; Thomas Musacchio ; Andreas Nadke ; Alma Osmanovic ; Gabriele Ritter ; Katharina Röse ; Christopher Schippers ; Ludger Schöls ; Rebecca Schüle ; Jörg B Schulz ; Joachim Sproß ; Eveline Stasch ; Gilbert Wunderlich ; Alexander Münchau

BACKGROUND:

In 2017, the German Academy for Rare Neurological Diseases (Deutsche Akademie für Seltene Neurologische Erkrankungen; DASNE) was founded to pave the way for an optimized personalized management of patients with rare neurological diseases (RND) in all age groups. Since then a dynamic national network for rare neurological disorders has been established comprising renowned experts in neurology, pediatric neurology, (neuro-) genetics and neuroradiology. DASNE has successfully implemented case presentations and multidisciplinary discussions both at yearly symposia and monthly virtual case conferences, as well as further educational activities covering a broad spectrum of interdisciplinary expertise associated with RND. Here, we present recommendation statements for optimized personalized management of patients with RND, which have been developed and reviewed in a structured Delphi process by a group of experts.

METHODS:

An interdisciplinary group of 37 RND experts comprising DASNE experts, patient representatives, as well as healthcare professionals and managers was involved in the Delphi process. First, an online collection was performed of topics considered relevant for optimal patient care by the expert group. Second, a two-step Delphi process was carried out to rank the importance of the selected topics. Small interdisciplinary working groups then drafted recommendations. In two consensus meetings and one online review round these recommendations were finally consented.

RESULTS:

38 statements were consented and grouped into 11 topics: health care structure, core neurological expertise and core mission, interdisciplinary team composition, diagnostics, continuous care and therapy development, case conferences, exchange / cooperation between Centers for Rare Diseases and other healthcare partners, patient advocacy group, databases, translation and health policy.

CONCLUSIONS:

This German interdisciplinary Delphi expert panel developed consented recommendations for optimal care of patients with RND in a structured Delphi process. These represent a basis for further developments and adjustments in the health care system to improve care for patients with RND and their families.

19 Jan 2024·Wiener klinische Wochenschrift

Intramuscular botulinum toxin-A in complex regional pain syndrome resistant to standard treatment: a case report.

Article

Author: Yasemin Tombak ; Ozgur Zeliha Karaahmet ; Ece Unlu Akyuz

OBJECTIVE:

To present a patient with complex regional pain syndrome type 1 (CRPS-I) and improvement of contracture of hand muscles and grip strength after successful treatment with botulinum neurotoxin‑A (BoNT-A).

CASE:

A 53-year-old woman with CRPS‑I experienced severe allodynia, swelling and autonomic changes in the left hand after a distal radius fracture. Over the succeeding months, she developed contracture of the left hand muscles which was treated with injection of BoNT‑A into the hand muscles (10 points).

RESULTS:

In the patient treatment with BoNT‑A an improvement was seen in the hand range of motion (ROM) and grip strength.

CONCLUSION:

Successful results can be obtained with BoNT‑A injection in treatment-resistant CRPS‑I cases which may develop joint contracture.

17 Jan 2024·Journal of neuroinflammation

Transient immune activation without loss of intraepidermal innervation and associated Schwann cells in patients with complex regional pain syndrome.

Article

Author: Beate Hartmannsberger ; Sabrina Scriba ; Carolina Guidolin ; Juliane Becker ; Katharina Mehling ; Kathrin Doppler ; Claudia Sommer ; Heike L Rittner

BACKGROUND:

Complex regional pain syndrome (CRPS) develops after injury and is characterized by disproportionate pain, oedema, and functional loss. CRPS has clinical signs of neuropathy as well as neurogenic inflammation. Here, we asked whether skin biopsies could be used to differentiate the contribution of these two systems to ultimately guide therapy. To this end, the cutaneous sensory system including nerve fibres and the recently described nociceptive Schwann cells as well as the cutaneous immune system were analysed.

METHODS:

We systematically deep-phenotyped CRPS patients and immunolabelled glabrous skin biopsies from the affected ipsilateral and non-affected contralateral finger of 19 acute (< 12 months) and 6 chronic (> 12 months after trauma) CRPS patients as well as 25 sex- and age-matched healthy controls (HC). Murine foot pads harvested one week after sham or chronic constriction injury were immunolabelled to assess intraepidermal Schwann cells.

RESULTS:

Intraepidermal Schwann cells were detected in human skin of the finger-but their density was much lower compared to mice. Acute and chronic CRPS patients suffered from moderate to severe CRPS symptoms and corresponding pain. Most patients had CRPS type I in the warm category. Their cutaneous neuroglial complex was completely unaffected despite sensory plus signs, e.g. allodynia and hyperalgesia. Cutaneous innate sentinel immune cells, e.g. mast cells and Langerhans cells, infiltrated or proliferated ipsilaterally independently of each other-but only in acute CRPS. No additional adaptive immune cells, e.g. T cells and plasma cells, infiltrated the skin.

CONCLUSIONS:

Diagnostic skin punch biopsies could be used to diagnose individual pathophysiology in a very heterogenous disease like acute CRPS to guide tailored treatment in the future. Since numbers of inflammatory cells and pain did not necessarily correlate, more in-depth analysis of individual patients is necessary.

News (Medical) associated with Reflex Sympathetic Dystrophy

14 Jul 2023

·www.prnewswire.com

Netflix' "Take Care of Maya" Brought the Disease CRPS Into Public Awareness, Now Parents Are Asking if They or Their Children Have It

The Netflix documentary Take Care of Maya has raised awareness of, and many questions about, CRPS. First among them is, "Do I have it." Here is how to self-diagnose the signs of CRPS and where to look for the right medical help. MILFORD, Conn., July 14, 2023 /PRNewswire/ -- CRPS, or Complex Regional Pain Syndrome, is a serious, incurable disease that may not be as rare as it is rarely diagnosed. The good news is that if it is diagnosed early, it can be put into remission, often for a lifetime. RSDSA, the international CRPS support group, shows you how to tell if you or a loved one may have CRPS and where to get the right help. Just follow this link to find out if You or Your Child Has CRPS. Continue Reading CRPS, also known as Reflex Sympathetic Dystrophy, is rare, but as more pediatricians become aware of it, it may not be so rare in all ages as it has been rarely diagnosed. That's important because treatment within a month or two of onset can avoid long-term disability and a lifetime of misery in many cases. The Netflix documentary "Take Care of Maya" has raised awareness of, and many questions about CRPS. RSDSA has answers. Tweet this If you or a loved one has pain that is getting worse, especially if it is more severe than one would expect from the original injury, trauma, or medical procedure, and that pain is: Described as deep, aching, cold, or burning, especially with increased skin sensitivity, Persistent and excessive and does not subside with healing, Moderate to severe caused by something that should not cause pain at all such as the touch of clothing, touching a room temperature metal or stone object, or taking a shower, In areas that should not be painful at all, Accompanied by abnormal swelling, sweating, skin color changes, hair and/or nail growth, Associated with abnormal skin temperature, that is, one side of the body, a foot, or a hand, warmer or colder than the other by more than 1°C or 2°F, Limited range of motion, weakness, or other motor disorders including paralysis or dystonia, which is involuntary, repetitive movement. Follow the link to our article to learn more about how to find professional help. For more information on CRPS and RSDSA, visit the RSDSA website. Contact James Broatch, Executive Vice President 203-877-3790 SOURCE RSDSA

10 May 2023

·www.prnewswire.com

HLA Typing Market worth $2.1 billion | MarketsandMarkets

CHICAGO, May 10, 2023 /PRNewswire/ -- In the near future, the HLA typing industry is poised for significant advancements and growth. HLA typing plays a crucial role in various areas, such as organ transplantation, disease diagnosis, and personalized medicine. With advancements in genomic technologies and bioinformatics, the process of HLA typing is expected to become more efficient, accurate, and accessible. Next-generation sequencing (NGS) technologies, coupled with advanced data analysis algorithms, will enable high-throughput and cost-effective HLA typing, allowing for the identification of HLA alleles with higher resolution. Additionally, the integration of artificial intelligence and machine learning algorithms will further enhance the accuracy and efficiency of HLA typing, enabling more precise matching for transplantation and improved disease diagnosis. Furthermore, the emergence of point-of-care testing devices and portable sequencing platforms will bring HLA typing capabilities closer to the patients, facilitating rapid and decentralized testing. These advancements in the HLA typing industry hold great potential for improving patient outcomes, advancing transplantation medicine, and supporting personalized treatment approaches in the field of immunogenetics. HLA Typing Market in terms of revenue was estimated to be worth $1.4 billion in 2022 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 6.5% from 2022 to 2028 according to a new report by MarketsandMarkets™. The neurovascular devices market is mainly driven by rising incidence of neurovascular diseases, availability of medical reimbursements for neurovascular procedures, expansion of healthcare infrastructure across emerging economies, increased focus of players on boosting the research in novel neurovascular devices, and growing demand for minimally invasive surgical procedures. Download an Illustrative overview: Browse in-depth TOC on "HLA Typing Market" 180 - Tables 37 - Figures 223 - Pages HLA Typing Market Scope: The molecular assay technologies segment accounted for the largest share of 86.5% in 2022, by technology segment. Based on technology, the HLA typing market is segmented into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment accounted for the largest market share in 2022. The large share of the segment is attributed to the benefits of molecular assay technologies over non-molecular assays, such as low turnaround times, high procedural efficacy, multi-sample study capabilities, and real-time sample analysis. Molecular assay techniques are used in HLA typing for applications such as donor-recipient cross-matching, cancer and autoimmune disease diagnostics, infectious disease diagnostics, and transfusion. This market is segmented into PCR-based molecular assays and sequencing-based molecular assays. The growing demand for molecular assays is mainly attributed to their technological benefits over non-molecular assays, such as low turnaround times, high procedural efficacy, and real-time sample analysis. Other factors supporting market growth include growing applications in patient profiling, rising public-private investments for product development, and increasing evidence for the clinical efficacy of molecular assay techniques, coupled with rising technological advancements in molecular diagnostics (such as PCR and NGS). The diagnostic applications segment is anticipated to register highest CAGR during the forecast period. Based on application, the diagnostic applications market is segmented into Donor Recipient Cross Match, Cancer Diagnosis & Prevention, Infectious & Non-infectious disease testing, Transfusion Therapy and Others. The diagnostic applications segment accounted for the highest CAGR of 6.5% during the forecast period. The diagnostic applications segment is also projected to grow at the highest CAGR during the forecast period owing to the rising technological advancements in molecular assay techniques; increasing adoption of molecular assays for pathogen testing in infectious and non-infectious disease testing; and the growing incidence of chronic and infectious diseases. North America to dominate the global HLA Typing Market Based on the region, the HLA Typing Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America accounted for the largest share of neurovascular devices market. The large share of North America can be attributed to the high adoption of HLA typing devices in the region, the strong presence of companies operating in the market, and the availability of significant R&D investments for product development. Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to the presence of a large target patient population, rising awareness on the advantages HLA typing, geographical expansion of players in region, and government initiatives to modernize & expand healthcare infrastructure. Inquiry Before Buying: HLA Typing Market Dynamics: Drivers: Rising number of organ transplantation procedures Rising technological advancements in HLA typing Increasing funding investments for research activities Growing prevalence of infectious diseases Restraints: High cost of HLA typing products Limited reimbursements for target procedures Opportunities: Rising adoption of cross-matching and chimerism testing procedures Growing awareness of organ donations Challenges: Limited number of organ donations and long waiting lists for transplantations Shortage of skilled professionals Key Market Players: Major players in neurovascular devices market include Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux S.A. (France). Other players in the market are Immucor, Inc. (US), Illumina, Inc. (US), Luminex Corporation (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), GenDx (Netherlands), and Biofortuna (UK), among others. Get 10% Free Customization on this Report: Recent Developments: In March 2023, BioRad received The company received AOAC International and AFNOR approval for its iQ-Check kits, which are used with the CFX Opus Deepwell Real-time PCR System In August 2022 Roche developed a new digital Light cycler system that helps determine a patient's cancer. In May 2022, CareDx received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT software. These AlloSeq are used in patients who have received Hematopoietic cell transplantation. HLA Typing Market Advantages: Improved Organ Transplantation Success: Accurate HLA typing plays a critical role in organ transplantation. Matching the human leukocyte antigen (HLA) profile between the donor and recipient increases the chances of transplant success and reduces the risk of rejection. HLA typing enables precise matching, resulting in improved patient outcomes and increased transplant success rates. Enhanced Disease Diagnosis and Treatment: HLA typing is utilized in the diagnosis and treatment of various immune-related disorders, including autoimmune diseases, allergies, and certain cancers. By identifying specific HLA alleles associated with these conditions, healthcare professionals can tailor treatment plans and therapies to individual patients, resulting in more effective and personalized care. Advancement of Precision Medicine: The field of precision medicine aims to deliver targeted treatments based on an individual's genetic makeup. HLA typing provides valuable information about an individual's immune system and genetic variability, allowing for personalized treatment selection and dosing optimization. This approach reduces the likelihood of adverse reactions, improves treatment efficacy, and enhances overall patient care. Expansion of Transfusion Medicine: HLA typing is crucial in blood transfusion compatibility testing. Matching the HLA antigens between the donor and recipient minimizes the risk of transfusion reactions, ensuring safe and compatible blood transfusions. This advancement has improved the overall safety and success of transfusion medicine. Research and Scientific Advancements: HLA typing serves as a fundamental tool in immunological research, facilitating studies on disease associations, population genetics, and immune response variability. By analyzing HLA data, researchers can gain insights into disease mechanisms, population diversity, and immunogenetics, leading to a deeper understanding of human health and the development of new therapies. Rapid Technological Advancements: The HLA typing market benefits from ongoing technological advancements, such as next-generation sequencing (NGS), high-resolution molecular techniques, and advanced data analysis algorithms. These advancements enable faster, more accurate, and cost-effective HLA typing, making it accessible to a larger population and facilitating widespread adoption in clinical practice. Overall, the HLA typing market offers significant advantages, including improved organ transplantation outcomes, personalized medicine approaches, enhanced disease diagnosis and treatment, advancements in transfusion medicine, scientific research opportunities, and rapid technological progress. These advantages contribute to the growing importance and widespread utilization of HLA typing in the field of healthcare. Related Reports: Transplant Diagnostics Market - Global Forecasts to 2028 Digital PCR Market - Global Forecasts to 2028 Next Generation Sequencing Market - Global Forecasts to 2027 Molecular Diagnostics Market - Global Forecasts to 2027 HLA Typing for Transplant Market - Global Forecasts to 2025 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: Visit Our Website: Content Source: Logo: SOURCE MarketsandMarkets

Diagnostic Reagents

04 May 2023

·www.prnewswire.com

Neurovascular Devices Market worth $5.5 billion | MarketsandMarkets

CHICAGO, May 4, 2023 /PRNewswire/ -- The neurovascular devices industry is expected to experience significant growth in the near future, driven by increasing demand for these devices to treat neurological disorders such as stroke, brain aneurysms, and AVMs. Advancements in technology, such as the development of more precise and less invasive devices, are also expected to drive growth. Additionally, the industry is attracting significant investments, leading to the development of new and innovative products. The market is expanding geographically, with increasing demand in developing countries, providing additional growth opportunities. However, challenges such as high costs associated with these devices and the need for skilled healthcare professionals to operate them may impede growth. Overall, the neurovascular devices industry is poised for growth in the near future, as advancements in technology and increasing demand for neurological treatments drive market expansion. Neurovascular Devices Market in terms of revenue was estimated to be worth $3.6 billion in 2023 and is poised to reach $5.5 billion by 2028, growing at a CAGR of 8.7% from 2023 to 2028 according to a new report by MarketsandMarkets™. The neurovascular devices market is mainly driven by rising incidence of neurovascular diseases, availability of medical reimbursements for neurovascular procedures, expansion of healthcare infrastructure across emerging economies, increased focus of players on boosting the research in novel neurovascular devices, and growing demand for minimally invasive surgical procedures. Download an Illustrative overview: Browse in-depth TOC on "Neurovascular Devices Market" 223 - Tables 37 - Figures 263 - Pages Neurovascular Devices Market Scope: However, shortage of skilled neurosurgeons and high procedural cost of neurovascular, stringent regulatory approval process are some of the key challenge faced by the leading players in the global neurovascular devices market. Cerebral Aneurysms Segment is expected to account for the largest neurovascular devices market share in 2022, by disease pathology Based on disease pathology, the neurovascular devices market is segmented into cerebral aneurysm, ischemic strokes, carotid artery stenosis, arteriovenous malformations & fistulas, and other disease pathologies (includes cavernous malformations and moyamoya disease). The cerebral aneurysm segment is anticipated to hold the largest market share of neurovascular devices market. The increasing market demand for neurovascular devices for aneurysm treatment can be attributed mainly to the presence of neuro-interventional devices for cerebral aneurysm such as embolic coils, increase in the technological advancement in the neurovascular devices, and rise in the cases of cerebral aneurysm globally. The ambulatory care centers segment is anticipated to register highest CAGR during the forecast period. Based on end user, the neurovascular devices market is segmented into hospitals & surgical centers, ambulatory care centers, and research laboratories and academic institutes. The ambulatory care centers segment is projected to register the highest CAGR during the forecast period. Rising number of ambulatory surgery centers across developed countries, along with the ease of scheduling, the focused clinical staff, the improved productivity and the increased safety, and efficacy of these centers, and growing preference of minimally invasive surgical processes are the major factors that are expected to drive the growth of ambulatory care centers segment in the coming years. North America to dominate the global neurovascular devices market Based on the region, the neurovascular devices market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America accounted for the largest share of neurovascular devices market. The large share of North America can be attributed to the high adoption of neurovascular devices in the region, the strong presence of device manufacturers, and the availability of significant R&D investments for product development. Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to the presence of a large target patient population, rising awareness on the advantages of minimally invasive neurosurgical processes., geographical expansion of players in region, and government initiatives to modernize & expand healthcare infrastructure. Inquiry Before Buying: Neurovascular Devices Market Dynamics: Drivers: Rising incidence of neurovascular diseases Availability of medical reimbursements for neurovascular procedures Expansion of healthcare infrastructure across emerging economies Rising demand for effective neurovascular therapies Restraints: Shortage of skilled neurosurgeons High procedural cost of neurovascular surgeries and associated products Opportunities: Rising R&D activities for neurovascular therapies Growing preference for minimally invasive neurosurgical procedures Challenges: Stringent regulatory approval process for medical devices Key Market Players: Major players in neurovascular devices market include Stryker (US), Johnson & Johnson (US), Medtronic plc (US), Terumo Corporation (Japan), and Penumbra, Inc. (US). Get 10% Free Customization on this Report: Recent Developments: In December 2022, Stryker (US) established a new research & development facility at International Park, Gurgaon, India, intending to accelerate innovations in neurovascular devices for stroke treatment In February 2022, Johnson & Johnson (US) launched the EMBOGUARD, a balloon guide catheter for treating acute ischemic stroke. In January 2021, Penumbra, Inc. (US) and Genesis Medtech (Australia) collaborated to expand Penumbra's market capabilities in China by commercializing and producing novel neurovascular products in China. Neurovascular Devices Market Advantages: Improved patient outcomes: Neurovascular devices are designed to diagnose and treat various neurological disorders such as aneurysms, stroke, and arteriovenous malformations (AVMs). These devices have shown to improve patient outcomes by reducing the incidence of complications, minimizing the risk of bleeding, and improving patient recovery time. Increased demand: The increasing prevalence of neurological disorders such as stroke, brain aneurysms, and AVMs has led to a growing demand for neurovascular devices. This trend is expected to continue as the population ages and the incidence of these disorders increases. Technological advancements: Neurovascular devices are undergoing continuous technological advancements, resulting in improved safety, efficacy, and ease of use. These advancements have led to the development of devices that are more precise, durable, and less invasive, resulting in better patient outcomes. Growing investments: The neurovascular devices market has attracted significant investments in recent years due to its potential for growth and profitability. This investment has resulted in the development of new and innovative products, as well as increased research and development activities. Market expansion: The neurovascular devices market is expanding geographically, with increasing demand for these devices in developing countries. This expansion is expected to provide significant growth opportunities for the market in the coming years. Neurovascular Devices Market - Report Highlights: Recession Impact Analysis: The existing report includes an analysis of the impact of recession on the market overview section. Newer and improved representation of financial information: The new edition of the report provides updated financial information till 2022-2023 (depending on the availability) for each listed company in a graphical representation in a single diagram (instead of multiple tables). This will allow for the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating country/region, and business segment focus in terms of the highest revenue-generating segment. Recent Market Developments: Recent developments are helpful to know the market trend and growth strategies adopted by players in the market. The report provides the updated developments in terms of acquisitions, agreements, expansions, and agreements/collaboration etc. Latest Product portfolio: The new edition of the report provides an updated product portfolio of the companies profiled in the report. Competitive leadership mapping: The competitive landscape chapter has been updated with the market evaluation matrix. The competitive landscape also includes the market share analysis for 2023, updated competitive leadership mapping, and competitive situation & trends. This report version has added the vendor dive matrix, covering a comprehensive study of the key vendors. Competitive leadership mapping has also been done for start-ups/SMEs. Related Reports: Interventional Cardiology Devices Market - Global Forecasts to 2027 Neuromodulation Market - Global Forecasts to 2027 Microcatheters Market - Global Forecasts to 2027 Peripheral Vascular Devices Market - Global Forecasts to 2026 Ambulatory Surgical Centers Market - Global Forecasts to 2025 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: Visit Our Website: Content Source: Logo: SOURCE MarketsandMarkets

Analysis

Perform a panoramic analysis of this field.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis